GlassScriptPhysician profile
Isham W Pauli
NPI 1477639664
$2,363.52
in general payments reported to CMS, 2019-2025
26 companies · $433 in 2025
The $433 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $213 · 2021: $233 · 2022: $309 · 2023: $438 · 2024: $399 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,271.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $462.07 | 2022-2025 | |
| Ironshore Pharmaceuticals INC. | $364.87 | 2019-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $267.46 | 2019-2025 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Glaxosmithkline, LLC. | $142.06 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Cranial Technologies, INC | $123.75 | 2021-2024 | Doc Band |
| Alk-Abello, INC | $114.13 | 2025 | Neffy, Odactra, Ragwitek |
| Collegium Pharmaceutical, INC. | $109.29 | 2025 | Jornay Pm |
| Corium, LLC | $104.02 | 2021-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $78.69 | 2019-2021 | |
| Verrica Pharmaceuticals INC. | $77.13 | 2023-2024 | Ycanth |
| Arbor Pharmaceuticals, INC. | $75.06 | 2019-2020 | |
| Pfizer INC. | $69.32 | 2019-2025 | |
| Tris Pharma INC | $66.52 | 2019-2022 | |
| Neos Therapeutics, LP | $62.39 | 2019-2021 | |
| Shire North American Group INC | $52.83 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $24.84 | 2020 | |
| Supernus Pharmaceuticals, INC. | $21.20 | 2025 | Qelbree |
| Harmony Biosciences LLC | $20.39 | 2025 | |
| Novartis Pharmaceuticals Corporation | $20.36 | 2019 | |
| Lnhc, INC | $19.98 | 2025 | Zelsuvmi |
| Dexcom, INC. | $17.68 | 2021 | |
| Rhodes Pharmaceuticals L.P. | $17.48 | 2019 | |
| Dermira, INC. | $15.71 | 2020 | |
| Seqirus USA INC | $13.29 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $11.98 | 2019 | |
| Vertical Pharmaceuticals, LLC | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isham Pauli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.